Arvelige erytrocytsygdomme

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Arvelige erytrocytsygdomme. / Glenthøj, Andreas.

I: Ugeskrift for Laeger, Bind 183, Nr. 42, V01210080, 18.10.2021.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Glenthøj, A 2021, 'Arvelige erytrocytsygdomme', Ugeskrift for Laeger, bind 183, nr. 42, V01210080. <https://content.ugeskriftet.dk/sites/default/files/scientific_article_files/2021-10/v01210080_web.pdf>

APA

Glenthøj, A. (2021). Arvelige erytrocytsygdomme. Ugeskrift for Laeger, 183(42), [V01210080]. https://content.ugeskriftet.dk/sites/default/files/scientific_article_files/2021-10/v01210080_web.pdf

Vancouver

Glenthøj A. Arvelige erytrocytsygdomme. Ugeskrift for Laeger. 2021 okt. 18;183(42). V01210080.

Author

Glenthøj, Andreas. / Arvelige erytrocytsygdomme. I: Ugeskrift for Laeger. 2021 ; Bind 183, Nr. 42.

Bibtex

@article{7b67d84653324e429c81d205d4f80111,
title = "Arvelige erytrocytsygdomme",
abstract = "Hereditary anaemias are the most prevalent genetic disorders worldwide. Until recently, treatment options were mostly supportive or surgical, i.e. splenectomy. Recently, several medical treatments designed for frequent haemoglobinopathies such as thalassaemia and sickle cell disease have become available, and numerous new clinical trials hold promise of many more to come. Even rare anaemias such as pyruvate kinase deficiency have promising clinical trials with targeted therapies. Together, these herald hope for future treatment options for patients living with hereditary anaemias, which is discussed in this review.",
keywords = "Anemia, Hemolytic, Congenital Nonspherocytic, Anemia, Sickle Cell, Hemoglobinopathies, Humans, Splenectomy, Thalassemia",
author = "Andreas Glenth{\o}j",
year = "2021",
month = oct,
day = "18",
language = "Dansk",
volume = "183",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "42",

}

RIS

TY - JOUR

T1 - Arvelige erytrocytsygdomme

AU - Glenthøj, Andreas

PY - 2021/10/18

Y1 - 2021/10/18

N2 - Hereditary anaemias are the most prevalent genetic disorders worldwide. Until recently, treatment options were mostly supportive or surgical, i.e. splenectomy. Recently, several medical treatments designed for frequent haemoglobinopathies such as thalassaemia and sickle cell disease have become available, and numerous new clinical trials hold promise of many more to come. Even rare anaemias such as pyruvate kinase deficiency have promising clinical trials with targeted therapies. Together, these herald hope for future treatment options for patients living with hereditary anaemias, which is discussed in this review.

AB - Hereditary anaemias are the most prevalent genetic disorders worldwide. Until recently, treatment options were mostly supportive or surgical, i.e. splenectomy. Recently, several medical treatments designed for frequent haemoglobinopathies such as thalassaemia and sickle cell disease have become available, and numerous new clinical trials hold promise of many more to come. Even rare anaemias such as pyruvate kinase deficiency have promising clinical trials with targeted therapies. Together, these herald hope for future treatment options for patients living with hereditary anaemias, which is discussed in this review.

KW - Anemia, Hemolytic, Congenital Nonspherocytic

KW - Anemia, Sickle Cell

KW - Hemoglobinopathies

KW - Humans

KW - Splenectomy

KW - Thalassemia

M3 - Tidsskriftartikel

C2 - 34709160

VL - 183

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 42

M1 - V01210080

ER -

ID: 305547064